DataM Intelligence | competitive Intelligence NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibito ...

Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas. The first active clinical trial site is the Royal North Shore Hospital in Sydney, Australia, which is ...

Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas. Pasithea has selected Novotech (Australia) Pty Limited as its clinical research organization (CRO ...

The trial aims to provide insights on both plexiform and cutaneous neurofibromas and is supported by an anticipated Australian R&D Tax Incentive refund of up to 48.5% of eligible costs.

Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas. The first active clinical trial site is the Royal North Shore Hospital in Sydney, Australia, which is ...

Plexiform neurofibromas can cause severe disability, while cutaneous neurofibromas—benign but often numerous tumours—result in significant cosmetic and psychological distress. Treatment ...

Neurofibromatosis type 1 is associated with a variety of symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and, in 30-50% of patients, tumours develop on the nerve sheaths ...

Mobile images may be reliable for assessing cutaneous neurofibroma (cNF) features in patients with neurofibromatosis type 1 (NF1), according to a crowdsourced registry study that also suggests ...